OccuLogix partners with Japanese firm

Article

OccuLogix and the Japanese company Asahi Kasei Medical have announced a distribution agreement for the 2nd generation polysulfone Rheofilter component of OccuLogix's dry age-related macular degeneration (AMD) treatment system, Rheo.

OccuLogix and the Japanese company Asahi Kasei Medical have announced a distribution agreement for the 2nd generation polysulfone Rheofilter component of OccuLogix's dry age-related macular degeneration (AMD) treatment system, Rheo.

Under the terms of the agreement, OccuLogix has exclusive rights to commercialize the Rheofilter in the US, Canada, Mexico, certain Caribbean countries, Columbia, Venezuela, New Zealand and Australia. It also retains non-exclusive commercialization rights in Italy.

As part of the deal, Asahi will contribute $3 million toward the costs of a new study examining the Rheo System, which is intended to support OccuLogix's pre-market approval application with the FDA.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.